A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food and Drug Administration last month. Gilead Sciences’ lenacapavir is so effec ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection.

Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the ...

Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD). Such investors are ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...

Gilead Sciences, a heavyweight in the biotech sector, continues to demonstrate strong relative strength trading just 5% below its 52-week high, compared with 16% for the SPDR Biotech ETF. The stock ...

Brian Hodous, Ph.D., promoted to chief scientific officer-- Vivek Kadambi, Ph.D., joins Recludix as senior vice president of non-clinical scienc ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention as a tool ...